USA
-
Esperion buys Corstasis for USD255M to launch Enbumyst nasal spray for edema
The self-administered nasal spray therapy bridges the gap between oral and intravenous diuretic treatments, offering patients an outpatient option for managing their condition.
-
CordenPharma Colorado to scale peptide development at new LEED Gold facility
The LEED Gold-certified facility features flexible laboratory configurations and advanced mechanical and utility systems, enabling researchers to conduct intricate scientific research.
-
Abbott’s new CardioMEMS HERO Heart Failure Reader wins FDA approval
Abbott engineered the HERO reader to be 60% lighter than its predecessor, making it practical for daily use and convenient enough for patients to carry during travel.
-
TECLens conducts first clinical trial for non-surgical vision correction technology
The proprietary CXLens system delivers patterned ultraviolet light to reshape the cornea while keeping the epithelium—the eye’s protective outer layer—completely intact.
-
Teva secures USD400M from Blackstone to advance bowel disease drug development
The Israeli pharmaceutical company will receive the funding over four years to support ongoing trials of the anti-TL1A antibody, which Teva is co-developing with Sanofi.
-
BD gets FDA approval for Surgiphor 1,000 ml antimicrobial irrigation system
The newly cleared system allows clinicians to mechanically loosen and remove debris and microorganisms from wounds during powered irrigation procedures.
-
Natco Pharma introduces generic Pomalidomide capsules in the US market for multiple myeloma treatment.
The new generic formulation matches the composition of Celgene’s original Pomalyst medication and comes in four different strengths: 1mg, 2mg, 3mg, and 4mg.
-
PharmaEssentia invests USD46M in Puerto Rico’s manufacturing facility
The new manufacturing hub represents a core strategic priority for PharmaEssentia as the company works to strengthen its supply chain, increase production flexibility, and diversify its geographic footprint.
-
Johnson & Johnson commits USD55B to US manufacturing expansion amid tariff concerns
The new facility will generate approximately 500 permanent biomanufacturing positions once operational.
-
AbbVie invests USD380M in Illinois manufacturing facilities to increase API production
AbbVie plans to hire 300 new employees for the facilities, targeting engineers, scientists, manufacturing operators, and lab technicians in the North Chicago area.